Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Erleada (apalutamide) and Pfizer/Astellas’ Xtandi (enzalutamide). ... They point to a benign side-effect profile, attributed to a novel structure that means that unlike enzalutamide and apalutamide it is unable to cross the blood-brain barrier and

Latest news

Merck puts prostate cancer firmly in Keytruda’s sights

not yet approved for prostate cancer but making its way through late-stage testing – as well as chemotherapy with docetaxel and prednisone, and hormone therapy with Astellas/Pfizer’s Xtandi (enzalutamide)
J&J’s Erleada cleared for early prostate cancer in Europe

receptor inhibitor Xtandi (enzalutamide) for the same indication.
Nektar confirms BMS deal for NKTR-214 is on track

He also revealed that Nektar has agreed to test NKTR-214 with Pfizer’s PD-L1 inhibitor Bavencio (avelumab), PARP inhibitor talazoparib and anti-androgen drug enzalutamide in indications outside the
Generic threat looms to J&J’s blockbuster Zytiga in US

Pfizer’s rival CRPC therapy Xtandi (enzalutamide) could also come under pressure form the entry of low-cost competitors.
Reference price bill tabled in US House and Senate

savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).

More from news
Approximately 12 fully matching, plus 48 partially matching documents found.

Latest Intelligence

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Medical Writer/ Senior Medical Writer opportunities – Macclesfie...: competitive salary and benefits package

Subscribe to our email news alerts

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

My MS journey: one patient's search for innovation: David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.: Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?: Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...